Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2018
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms CEDAR
- 28 Jun 2016 Status changed from not yet recruiting to recruiting.
- 18 Feb 2016 Planned initiation date changed from 1 Jan 2016 to 1 May 2016, according to ClinicalTrials.gov record.
- 11 Jan 2016 New trial record